Spots Global Cancer Trial Database for Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)

Official Title: A Prospective Multicenter Non-randomized Controlled Study of Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma

Study ID: NCT01409499

Conditions

Hepatectomy

Hepatocellular Carcinoma

Sorafenib

Interventions

hepatic resection

transcatheter hepatic arterial chemoembolization

sorafenib

Study Description

Brief Summary: The standard treatment choice for advanced hepatocellular carcinoma (HCC) is sorafenib, and its efficacy is limited. More active treatments were performed in patients with advanced HCC in China, which include radical hepatectomy or TACE. The study is to investigate whether the active treatment will profit survival of patients, and to evaluate the safety.

Detailed Description: This is a prospective non-randomized controlled study. Patients with advanced hepatocellular carcinoma (BCLC C stage) who underwent palliative resection or TACE followed with Sorafenib or treated by sorafenib alone will be included. The patients will be divided to group A (palliative resection plus sorafenib), group B (palliative TACE plus sorafenib), and group C (sorafenib alone). The sample size will be about 200 cases altogether.